Last reviewed · How we verify

NCT07299097: HYPNOS

Epidemiology of Narcolepsy Type 1 and Type 2 in Spain

Recruiting now Last updated 5 March 2026
What this trial tests

trial testing No intervention in Narcolepsy Type 1 in 100 participants. Currently enrolling.

Timeline
2 December 2025
Primary endpoint
30 May 2026
30 May 2026

Quick facts

Lead sponsorTakeda
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment100
Start date2 December 2025
Primary completion30 May 2026
Estimated completion30 May 2026
Sites10 locations across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Takeda — full company profile →

Who can join

0 and older, any sex, with Narcolepsy Type 1 or Narcolepsy Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to find out how many people in Spain have been diagnosed with narcolepsy type 1 and type 2, and how many new participants are diagnosed each year. Narcolepsy is a rare sleep disorder that causes excessive daytime sleepiness. The researchers will look at medical records from hospitals across Spain to count participants with these conditions and understand patterns in diagnosis over time.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Narcolepsy Type 1

Currently open trials in the same condition.

Other Takeda trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07299097.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing